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Background and Aims: It is unclear whether obesity is associated with the development of 
inflammatory bowel disease despite compelling data from basic science studies. We therefore 
examined the association between obesity and risk of Crohn's disease (CD) and ulcerative colitis (UC). 
 
Methods: We conducted pooled analyses of 5 prospective cohorts with validated anthropometric 
measurements for body mass index (BMI) and waist-hip ratio (WHR) and other life-style factors. 
Diagnoses of CD and UC were confirmed through medical records or ascertained using validated 
definitions. We used Cox proportional hazards modelling to calculate pooled multivariable-adjusted 
HRs (aHRs) and 95% CIs. 
 
Results: Among 601,009 participants (age range: 18-98 years) with 10,110,018 person-years of follow-
up, we confirmed 563 incident cases of CD and 1047 incident cases of UC. Obesity (baseline BMI 
≥30kg/m2) was associated with an increased risk of CD (pooled aHR 1.34, 95% CI 1.05-1.71, I2=0%) 
compared with normal BMI (18.5 to <25kg/m2). Each 5kg/m2 increment in baseline BMI was associated 
with a 16% increase in risk of CD (pooled aHR 1.16, 95% CI 1.05-1.22, I2=0%). Similarly, with each 
5kg/m2 increment in early adulthood BMI (age 18-20 years), there was a 22% increase in risk of CD 
(pooled aHR 1.22, 95% CI 1.05-1.40, I2=13.6%). An increase in WHR was associated with an increased 
risk of CD that did not reach statistical significance (pooled aHR across quartiles 1.08, 95% CI 0.97-
1.19, I2=0%). No associations were observed between measures of obesity and risk of UC.   
 
Conclusion: In an adult population, obesity as measured by BMI was associated with an increased risk 
of older-onset CD but not UC. 
 










The global incidence of the inflammatory bowel diseases (IBD), Crohn’s disease (CD) and 
ulcerative colitis (UC) has increased especially in developing countries that have witnessed a 
dramatic Westernization of lifestyle1. Over a similar time frame obesity is becoming increasingly 
prevalent worldwide2 and is one of the strongest risk factors for chronic disease morbidity and 
mortality3. As a major environmental factor in the development of autoimmune diseases4, obesity 
may contribute substantially to the etiopathogenesis of IBD, particularly in those with older-onset 
IBD, where relative to those with younger disease onset the overall contribution of the environment 
is significantly greater5.   
 Obesity is often linked to Westernized lifestyles such as physical inactivity and excess calorie 
consumption from meals high in refined grains and unhealthy fats. Adipocyte hypertrophy resulting 
from obesity generates a proinflammatory state through the secretion of inflammatory mediators 
including tumor necrosis factor (TNF)-α6,  and C-reactive protein (CRP)7. These are also elevated in 
IBD patients, especially TNF-α, whose pathogenic role is antagonized by anti-TNF therapies. Obesity 
is further associated with increased markers of bowel inflammation based on fecal calprotectin 
measurements8 and intestinal permeability9, biological hallmarks of IBD. Yet despite these 
compelling data, epidemiologic studies have failed to identify a consistent link between obesity and 
the risk of CD and UC10, 11. This is likely to be due to the significant limitations of previous studies that 
include retrospective design, sample size and inability to control for confounding from other 
important life-style exposures and lack of detailed measures of obesity.  
 We therefore investigated the relationship between measures of obesity and risk of CD and 
UC whilst addressing the methodological limitations of prior studies through a pooled analysis of 
several well-established prospective cohorts. These robust population-based cohorts had detailed 
and validated data on measures of obesity and lifestyle data offering us a unique opportunity to 











A pooled analysis of the primary data from five large prospective cohorts was conducted 
within the Dietary and Environmental Factors IN-IBD (DEFINe-IBD) study. DEFINe-IBD is an 
international consortium of cohort studies aimed at identifying environmental and lifestyle risk 
factors for IBD by analyzing harmonized individual-level data from multiple prospective cohorts 
using standardized criteria. The consortium includes the European Prospective Investigation into 
Cancer and Nutrition (EPIC), the Nurses’ Health Study (NHS) and NHSII, the Cohort of Swedish Men 
(COSM) and the Swedish Mammography Cohort (SMC). An overview of the study populations, design 
of each cohort and predefined inclusion criteria are given in the supplementary materials. All 
cohorts provided their primary individual level data for analyses related to this study. At baseline, we 
excluded individuals with missing baseline anthropometric measurements needed to determine 
body mass index (BMI), those with BMI <18.5kg/m2 (due to the possibility of underlying disease) and 
participants diagnosed with IBD prior to start of follow-up in each cohort.  We excluded incident 
cases of CD and UC diagnosed within the first 2 years of follow-up to minimize the possibility of 
reverse causation. 
 Each cohort’s ethics committee approved participation in this study. 
 
Exposure assessment 
Anthropometric measurements were obtained from baseline questionnaires to calculate BMI 
and waist-to-hip ratio (WHR) as measures of obesity. Where information on key variables including 
covariates (see below) were unavailable at baseline but were collected later, on subsequent 
questionnaires, the baseline was redefined as the later date. Therefore, baseline questionnaires were 
collected from EPIC participants from 1991-1997; NHS and NHSII participants in 1986 and 1993, 
respectively; and COSM and SMC participants in 1997. Self-reported weight in early adulthood (18-20 








participants’ height in early adulthood would be the same as that recorded at baseline12. For additional 
details see the supplementary materials. 
 
Assessment of covariates 
Total physical activity, total energy intake, dietary fiber and fat intake were calculated from 
baseline questionnaires for each cohort as summarized in the supplementary materials. Self-
reported smoking status at baseline was recorded as current, past or never. 
 
Outcome ascertainment 
Case ascertainment for CD and UC have been described in detail for EPIC10, NHS  and NHS 
II13, COSM and SMC14, 15 and a summary of IBD case ascertainment for each cohort is given in the 
supplementary materials.  
 
Statistical analysis 
Measures of obesity were modelled categorically and continuously. For the categorical 
analysis, BMI was modelled using cut points proposed by the World Health Organization (WHO): 
18.5-<25kg/m2 (normal), 25-<30kg/m2 (overweight) and ≥30kg/m2 (obese)16. We used BMI of 18.5-
<25kg/m2 as the referent category. Categorical analysis of WHR was modelled using the WHO 
definition of abdominal obesity (female >0.85, male >0.90)17 and as quartiles. Continuous analyses 
modelled per 5kg/m2 increase in BMI and for WHR per quartile and per unit increase. 
We calculated person-time for each participant from the date of the baseline questionnaire 
until the date of CD or UC diagnosis, death from another cause, loss to follow-up, or end of follow-
up, whichever came first. Minimally adjusted (age and sex) and multi-variable (MV)-adjusted hazard 
ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional hazards models 
for each cohort. Covariables were formatted to be consistently classified across all cohorts and 








(physical activity: n=38,418 (6.4%); smoking status: n=6,428 (1.0%); total energy intake: n=25,397 
(4.2%); total fiber intake: n=25,397 (4.2%); total fat intake: n=25,397 (4.2%)). Where the outcome 
was CD, MV-adjusted HRs were adjusted for sex (male/female), smoking status (non-smoker/ex-
smoker/current smoker), total energy intake (kcal/day), physical activity (MET hr/wk modelled as 
quartiles according to cohort distribution) and dietary fiber (g/day). For UC, MV-adjusted HRs 
models were similar but were adjusted for dietary fat (g/day) instead of dietary fiber. These 
variables were selected based on their known associations with risk of CD or UC18, 19. For models, in 
which baseline BMI was not the main exposure (i.e. WHR or BMI in early adulthood), BMI was 
included as a covariable in the model to examine the independent associations of our secondary 
exposures. Lastly, models that examined the relationship between change in weight from early to 
middle adulthood and risk of CD and UC were additionally adjusted for height and early adulthood 
weight but not baseline BMI. 
 Cohort-specific Cox proportional HRs were pooled using a fixed effect meta-analysis20. 
Heterogeneity between studies was evaluated using the Q and I2 statistic, I2>50% indicated 
substantial heterogeneity. In addition, we conducted sensitivity analyses to evaluate whether 
associations between BMI and risk of CD and UC were modified by age at start of follow-up (<50 
versus ≥50 years), sex (female versus male), and smoking status (never versus ever). Lastly, we also 
examined the association between BMI and risk of CD according to age of diagnosis (< 40 years, 40 - 
<60 years, ≥ 60 years). All P-values were 2-sided and <0.05 was considered statistically significant. 
 We calculated the population attributable risk conferred by obesity as defined by BMI 
(≥30kg/m2) to estimate the percentage of IBD cases that may have been preventable if participants 
had maintained a normal BMI assuming a causal relationship between BMI and IBD.  
 Stata 16.1/MP (StataCorp LLC) and SAS 9.4 (SAS Institute Inc) were used for analyses of 











Following exclusions our pooled cohort included 601,009 participants from 9 countries and 
71% were female. Over 10,110,018 person-years of follow-up with mean follow-up of 16 years, we 
identified 563 incident cases of CD (incidence rate, 6 cases/100,000 person-years) and 1047 incident 
cases of UC (incidence rate, 10 cases/100,000 person-years). Table 1 reports the baseline 
characteristics of participants categorized by BMI. Compared to participants in the lowest category 
of BMI, those in the highest category had higher WHR, were less physically active, and more likely to 
be smokers. 
For baseline BMI, we observed an increased risk of CD in those who were obese (BMI 
≥30kg/m2) in our minimally adjusted model (HR 1.27, 95% CI 0.97–1.68; I2=0%) when compared with 
participants in the lowest category of BMI (BMI 18.5-<25kg/m2) (Table 2) and for each 5kg/m2 
increase in baseline BMI, a statistically significant 10% increase in risk of CD (HR 1.10, 95% CI 1.00–
1.22; I2=0%). These associations were not altered after adjusting for known and potential risk factors 
for CD including smoking, physical activity and dietary fiber intake. Compared to participants in the 
lowest category of BMI the MV-adjusted HR of CD for participants with BMI ≥30 kg/m2 was 1.34 
(95% CI 1.05–1.71); I2=0%. Similarly, for every 5kg/m2 increase in baseline BMI, we observed a 16% 
increase in risk of CD (MV-adjusted HR 1.16, 95% CI 1.05–1.22).  We observed no heterogeneity in 
the association between the highest category of BMI (≥30kg/m2) or per 5kg/m2 increment in BMI 
and risk of CD across the five cohorts (Qstatistic=2.11, I2=0%, p=0.71 and Qstatistic=0.85, I2=0%, p=0.93, 
respectively).  We used data on worldwide prevalence of BMI ≥30kg/m2 from the WHO Global 
Health Observatory to estimate the population attributable risk for older-onset CD. In Western 
Europe and the US, the prevalence of obesity increased from 15%–29% at mid-point of the study 
(~2005) to 20%–36% towards the end of the study period (~2016), conferring an adjusted population 
attributable risk ranging from 5%–11% assuming a causal relationship between BMI and CD. 
In contrast to CD, we did not observe an association between those who were overweight 








adjusted models (Table 3). For every 5kg/m2 increase in BMI the minimally adjusted HR for UC was 
1.00 (95% CI 0.95–1.10) and MV-adjusted HR 1.00 (95% CI 0.90–1.05).  We observed no 
heterogeneity across cohorts in the association between the highest category of BMI (≥30) or per 
5kg/m2 increment in BMI and risk of UC across the five cohorts (Qstatistic=3.29, I2=0%, p=0.51 and 
Qstatistic=1.25, I2=0%, p=0.87, respectively).  
 We explored whether the association between baseline BMI and risk of CD and UC was 
consistent across several subgroups defined by sex, age, and smoking (Figure 1) and observed no 
evidence of effect modification (all Pinteraction≥0.44). We considered the possibility that the association 
between obesity and risk of CD may differ according to age of diagnosis, and therefore evaluated the 
associations according to different categories of age of diagnosis (18-<40, 40-<60 and ≥60 years). 
Compared to participants in the lowest category of BMI, participants with BMI ≥ 30 kg/m2 had MV-
adjusted HRs of  1.35, 95% CI 0.92-1.99 (Qstatistic=6.68, I2=40%, p=0.12) and 1.66, 95% CI 1.12-2.30 
(Qstatistic=4.57, I2=12%, p=0.33) for diagnosis of CD during middle age (40-<60 years) and older age (≥ 
60 years), respectively. We could not examine the association with younger-onset CD (18-<40 years) 
given limited numbers of cases in all the cohorts. Conducting an analysis limiting our cohort to 
participants with above average physical activity level in each cohort we observed a 22% increase in 
risk of CD with every 5kg/m2 increase in BMI (MV-adjusted HR=1.22, 95% CI 1.10–1.40) and no 
increase in risk of UC (MV-adjusted HR=1.00, 95% CI 0.90–1.16).  
Information on BMI in early adulthood (age 18–20 years) was available in just over two-
thirds of participants and we further explored the association between early adulthood BMI and risk 
of CD and UC. In those with an early adulthood BMI ≥25kg/m2 (i.e. overweight), the minimally 
adjusted HR of developing CD later in life was 1.52 (95% CI 1.15–1.99); I2=0% when compared to 
participants with an early adulthood BMI <25kg/m2. This estimate was not materially altered in MV-
adjusted analysis (HR 1.48, 95% CI 1.12–1.95; I2=0%). Similarly, we observed a 22% increase in risk of 
CD with every 5kg/m2 increase in early adulthood BMI (MV-adjusted HR=1.22, 95% CI 1.05–1.40; 








MV-adjusted HRs of developing UC Iater in life. For every 5kg/m2 increase in early adulthood BMI the 
MV-adjusted HR for UC was 1.05 (95% CI 0.90–1.22); I2=0%. We also examined the association 
between weight change from early adulthood (age 18-20 years) and mid-life (baseline in each 
cohort) and observed no significant associations with risk of CD or UC (Supplementary materials). 
However, in joint analysis of early adulthood BMI and weight change from early adulthood to mid-
life, the highest risk of CD was observed in participants with early adult BMI ≥25kg/m2 and the 
largest category of weight gain (≥10kg) (Figure 2). Compared to participants with BMI <25kg/m2 and 
no changes in weight (<2kg), the MV-adjusted HR of CD among those with BMI ≥25kg/m2 and ≥10kg 
change in weight was 2.14 (95% CI, 1.43–3.22; I2=38%).  
Finally, we evaluated the association between abdominal obesity and risk of CD and UC 
(Table 4). Compared to participants in the lowest quartile of WHR, the MV-adjusted HR for the 
second, third and highest quartile of WHR were associated with a non-statistically significant 
increased risk of CD (continuous HR per WHR quartile 1.08, 95% CI 0.98–1.19) and were unaffected 
by additional adjustments for baseline BMI (continuous HR per WHR quartile 1.08, 95% CI 0.97–
1.19). Similarly, assessing WHR as a continuous variable or based on the WHO WHR classification of 
abdominal obesity showed a non-statistically significant increased risk of CD in both these models 
(HR 1.02, 95% CI 0.97–1.07 and HR 1.09, 95% CI 0.85–1.40, respectively). No associations between 
WHR and risk of UC were observed in any of our models.  
 
DISCUSSION 
In a pooled analysis of over 600,000 participants in five prospective cohorts of 
predominantly middle-aged men and women from 9 western countries, we showed that obesity as 
measured by BMI, is associated with an increased risk of CD. Similarly, we found that BMI in early 
adulthood is associated with an increased risk of subsequently developing CD. These findings were 
consistent across multiple sensitivity and subgroup analyses, after accounting for unhealthy lifestyles 








by WHR, was associated with a non-statistically significant increased risk of CD. No associations were 
seen between any of these anthropometric measures and UC.  
Several biologically plausible mechanisms support our findings for an association between 
obesity and risk of CD. First, obesity causes adipocyte hypertrophy and dysfunction leading to the 
secretion of many adipokines and pro-inflammatory mediators that are elevated in those with active 
CD21. Second, levels of intestinal inflammation and permeability are associated with obesity8, 9, 22 and 
may facilitate bacterial translocation and loss of immune tolerance in the gastrointestinal tract. 
Third, CD is associated with ‘creeping’ of mesenteric fat, which is associated with fibrosis and 
stricturing23. Lastly, obesity has been linked to alterations in the gut microbiome24. We speculate 
these mechanisms are likely to have a greater role in the etiopathogenesis of CD compared to UC. 
To our knowledge this is the largest prospective adult cohort study to examine the 
relationship between different measures of obesity and risk of CD with the opportunity to adjust for 
multiple lifestyle and dietary exposures. Few studies have previously investigated the associations 
between obesity and IBD and both null10, 25 and positive associations11, 26-28 have been reported. 
Reasons for the inconsistences in these associations may be due to differences in study design, small 
sample size (≤100 cases), inability to control for risk factors such as smoking, limited number of cases 
for higher categories of obesity and different definitions of obesity.  
 Our findings are supported by prior work from the NHSII cohort11, part of this pooled 
analysis, which previously reported that obesity defined by BMI at baseline was associated with 
increased risk of CD. Interestingly, in this study, obesity defined by BMI at baseline in EPIC-IBD 
showed a positive association with CD, albeit not statistically significant. This is in contrast to 
previous data from EPIC-IBD which found no associations between BMI and CD10 and may be due to 
the analysis of EPIC-IBD as a full cohort, rather than the previous nested case-control design and 
additional follow-up time, affording greater statistical power. In addition, our observation that BMI 
in early adulthood is associated with increased risk of later-onset CD is supported by a study that 








 Since BMI in middle aged and older populations may not sufficiently represent the changes 
in fat distribution that are associated with age, we used WHR to assess the role of abdominal obesity 
and observed a non-statistically significant increased risk for CD. To date only a single study has 
found an association with WHR and IBD11 and based on the findings from our study with a 
significantly larger sample size any associations between WHR and the risk of CD or UC are likely to 
be very modest.  
There are several strengths to our study. First, the prospective design avoids the potential 
selection and recall biases of retrospective case-control studies. Second, accurate and validated 
measures for weight, height, waist and hip circumference ensured that recorded and self-reported 
anthropometric measures were valid and reproducible. Third, the diversity of included studies, large 
sample size and long follow-up period ensured that our estimates are generalizable to similar 
populations. Fourth, the availability of detailed and validated information on smoking, physical 
activity, dietary fiber and fat intakes allowed us to control for several risk factors that may have 
impacted our associations.  Fifth, all diagnoses of CD and UC were either confirmed through medical 
records or ascertained using validated definitions minimizing the risk of outcome misclassification. 
Finally, by pooling individual-level data, we were able to harmonize the exposures, covariates, 
outcomes and analytic modelling leading to little heterogeneity and decreased variability in effect 
estimates that can often be found in standard meta-analyses of the published literature. 
We acknowledge several limitations. First, our study participants were predominantly 
western middle-aged men and women and so our findings may not be generalizable to a non-
western or younger population at risk of IBD. That said, environmental exposures may play a greater 
role in IBD development of older-onset5. Second, our study was reliant mainly on anthropometric 
measures recorded at a single point in middle-age. The lack of repeated anthropometric measures in 
all cohorts over follow-up time, meant we were unable to assess the timepoint during the life-course 
at which obesity becomes a critical factor for risk of developing CD. However, we did have data on 








BMI at baseline. Finally, whilst we were able to account for several confounding factors, we further 
acknowledge that our observed associations are unable to demonstrate causality and may be related 
to residual confounding for factors such as early life exposures, which we are unable to adjust for. 
However, our results remained consistent after adjusting for known confounders and were 
consistent in several subgroups.  
 
Our data implies that the growing burden of obesity is likely contributing to the increasing 
incidence of CD worldwide. Together with previous observations that obesity modulates immune 
responses21, intestinal permeability9, 22 and alterations in the gut microbiota24 such pathways may 
play a more important role in the etiopathogenesis of CD compared with UC. Future work should 
consider examining the precise mechanisms through which obesity may influence the 










Table 1. Baseline characteristics of participants in each cohort according to extreme categories of BMI 
at baseline 
Table 2. Risk of Crohn’s disease according to BMI at baseline 
Table 3. Risk of ulcerative colitis according to BMI at baseline 
Table 4. Risk of Crohn’s disease and ulcerative colitis based on WHR (quartiles) and on WHO 
classification of WHR at baseline 
 
Figure 1. Association between baseline BMI and risk of Crohn’s disease and ulcerative colitis according 
to selected strata 
Figure 2. Multivariable-Adjusted Risk of Incident Crohn’s Disease and ulcerative colitis According to 
Early Adult BMI and Weight Change Since Early Adulthood 
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Table 1: Baseline characteristics of participants in each cohort according to extreme categories of body mass index at baseline* 
 EPIC NHS NHSII COSM SMC 
 

































Age at recruitment (years) 50.0 (11.2) 54.1 (8.7) 52.6 (7.2) 53.4 (7.0) 38.4 (4.6) 39.6 (4.5) 60.2 (10.0) 59.7 (9.0) 61.3 (9.4) 62.3 (8.5) 
Sex (female), % 73 62 100 100 100 100 0 0 100 100 
BMI (kg/m2) 22.5 (1.6) 33.3 (3.3) 22.3 (1.6) 34.3 (4.2) 22.0 (1.7) 35.5 (5.1) 23.1 (1.4) 32.6 (2.7) 22.5 (1.6) 33.0 (3.2) 
Waist to hip ratio 0.80 (0.08) 0.90 (0.10) 0.77 (0.17) 0.83 (0.11) 0.77 (0.07) 0.83 (0.09) 0.92 (0.06) 1.00 (0.09) 0.80 (0.09) 0.86 (0.10) 
Smoking, %           
Never 49 48 43 48 66 65 39 29 51 56 
Former 27 32 34 37 23 24 34 46 22 25 
Current 24 20 24 15 11 11 26 25 25 18 
Physical activity (MET-hr/wk) 35.1 (26.9) 29.9 (26.0) 16.0 (22.8) 9.8 (15.8) 22.9 (28.6) 15.2 (20.8) 41.8 (4.8) 40.7 (5.2) 42.6 (4.7) 41.6 (5.1) 
Energy Intake (kcal/day) 2109 (656) 2111 (733) 1754 (518) 1806 (549) 1776 (537) 1842 (571) 2699 (281) 2611 (1030) 1756 (555) 1713 (632) 
Total fat intake (g) 81 (31) 82 (34) 63 (23) 68 (24) 61 (22) 68 (24) 94 (36) 90 (42) 63 (24) 60 (26) 
Total fiber intake (g) 24 (8) 23 (8) 20 (8) 20 (8) 19 (8) 18 (8) 32 (13) 30 (15) 23 (9) 22 (10) 
*Abbreviations: Cohort of Swedish Men (CoSM), European Prospective Cohort Investigation into Cancer and Nutrition (EPIC), Nurses’ Health Study (NHS), and Swedish Mammography Cohort (SMC) 








Table 2: Risk of Crohn’s disease according to body mass index (BMI) at baseline* 
 Body Mass Index at Baseline (kg/m2) HR (95% CI) per 5 kg/m2 increase in BMI 
 18.5-<25 25-<30 ≥ 30  
EPIC     
Person-years of follow-up 2 229 220 1 701 427 642 078 - 
No. of cases 57 46 22 - 
Age and sex-adjusted HR (95% CI) 1.00 1.10 (0.74 – 1.63) 1.37 (0.84 – 2.23) 1.10 (0.90 – 1.34) 
Multivariable-adjusted HR (95% CI)§ 1.00 1.12 (0.75 – 1.66) 1.43 (0.89 – 2.31) 1.16 (0.95 – 1.40) 
NHS     
Person-years of follow-up 1 137 959 572 120 282 393 - 
No. of cases 82 48 22 - 
Age and sex-adjusted HR (95% CI) 1.00 1.14 (0.80 – 1.63) 1.06 (0.66 – 1.70) 1.10 (0.90 – 1.28) 
Multivariable-adjusted HR (95% CI)§ 1.00 1.16 (0.81 – 1.67) 1.09 (0.67 – 1.75) 1.10 (0.95 – 1.28) 
NHSII     
Person-years of follow-up 1 302 853 517 841 375 603 - 
No. of cases 82 31 31 - 
Age and sex-adjusted HR (95% CI) 1.00 1.22 (0.70 – 2.14) 1.04 (0.50 – 2.13) 1.10 (0.86 – 1.34) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.97 (0.64 – 1.47) 1.35 (0.89 – 2.06) 1.16 (0.95 – 1.34) 
COSM     
Person-years of follow-up 310 259 330 221 69 958 - 
No. of cases 40 34 12 - 
Age and sex-adjusted HR (95% CI) 1.00 0.80 (0.51 – 1.26) 1.33 (0.70 – 2.53) 1.05 (0.77 – 1.47) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.79 (0.50 – 1.26) 1.27 (0.66 – 2.44) 1.05 (0.77 – 1.40) 
SMC     
Person-years of follow-up 351 461 217 609 69 016 - 
No. of cases 29 16 11 - 
Age and sex-adjusted HR (95% CI) 1.00 0.93 (0.51 – 1.72) 2.01 (1.00 – 4.03) 1.22 (0.90 – 1.61) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.94 (0.51 – 1.73) 2.00 (0.99 – 4.03) 1.22 (0.90 – 1.61) 
Pooled age and sex adjusted HR (95% CI)  1.00 1.04 (0.85 – 1.28) 1.27 (0.97 – 1.68) 1.10 (1.00 – 1.22) 
Pooled multivariable HR (95% CI) 1.00 1.01 (0.83 – 1.23) 1.34 (1.05 – 1.71) 1.16 (1.05 – 1.22) 
*Abbreviations: Cohort of Swedish Men (CoSM), European Prospective Cohort Investigation into Cancer and Nutrition (EPIC), Nurses’ Health Study (NHS), and Swedish Mammography Cohort (SMC) 
§Adjusted for age at baseline (continuous), sex, smoking status (Never/Former/Current), Physical activity (Quartiles), Energy intake (continuous), dietary fiber (continuous).  I2 values for highest category of 








Table 3: Risk of ulcerative colitis according to body mass index (BMI) at baseline* 
 Body Mass Index at Baseline (kg/m2) HR (95% CI) per 5 kg/m2 increase in BMI 
 18.5-<25 25-<30 ≥ 30  
EPIC     
Person-years of follow-up 2 229 220 1 701 427 642 078 - 
No. of cases 148 135 53 - 
Age and sex-adjusted HR (95% CI) 1.00 1.01 (0.80 – 1.29) 1.10 (0.81 – 1.43) 1.10 (0.90 – 1.34) 
Multivariable-adjusted HR (95% CI)§ 1.00 1.02 (0.81 – 1.30) 1.13 (0.82 – 1.55) 1.05 (0.95 – 1.22) 
NHS     
Person-years of follow-up 1 137 959 572 120 282 393 - 
No. of cases 98 43 20 - 
Age and sex-adjusted HR (95% CI) 1.00 0.88 (0.62 – 1.26) 0.85 (0.52 – 1.37) 0.95 (0.82 – 1.16) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.87 (0.61 – 1.25) 0.83 (0.51 – 1.35) 0.95 (0.82 – 1.16) 
NHSII     
Person-years of follow-up 1 302 853 517 841 375 603 - 
No. of cases 120 47 30 - 
Age and sex-adjusted HR (95% CI) 1.00 1.20 (0.75 – 1.90) 0.91 (0.49 – 1.69) 1.10 (0.90 – 1.28) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.95 (0.68 – 1.33) 0.81 (0.54 – 1.23) 0.95 (0.86 – 1.10) 
COSM     
Person-years of follow-up 310 259 330 221 69 958 - 
No. of cases 86 126 14 - 
Age and sex-adjusted HR (95% CI) 1.00 1.38 (1.05 – 1.82) 0.72 (0.41 – 1.26) 1.00 (0.83 – 1.22) 
Multivariable-adjusted HR (95% CI)§ 1.00 1.34 (1.02 – 1.76) 0.68 (0.39 – 1.20) 0.95 (0.77 – 1.03) 
SMC     
Person-years of follow-up 351 461 217 609 69 016 - 
No. of cases 77 39 11 - 
Age and sex-adjusted HR (95% CI) 1.00 0.89 (0.60 – 1.31) 0.79 (0.42 – 1.48) 0.95 (0.77 – 1.22) 
Multivariable-adjusted HR (95% CI)§ 1.00 0.90 (0.61 – 1.33) 0.76 (0.40 – 1.44) 0.95 (0.77 – 1.22) 
Pooled age and sex adjusted HR (95% CI)  1.00 1.07 (0.93 – 1.24) 0.92 (0.74 – 1.14) 1.00 (0.95 – 1.10) 
Pooled multivariable HR (95% CI) 1.00 1.03 (0.91 – 1.19) 0.88 (0.72 – 1.08) 1.00 (0.90 – 1.05) 
*Abbreviations: Cohort of Swedish Men (CoSM), European Prospective Cohort Investigation into Cancer and Nutrition (EPIC), Nurses’ Health Study (NHS), and Swedish Mammography Cohort (SMC) 
§Adjusted for age at baseline (continuous), sex, smoking status (Never/Former/Current), Physical activity (Quartiles), Energy intake (continuous), dietary fat (continuous). I2 values for highest category of BMI 









Table 4: Risk of Crohn’s disease and ulcerative colitis based on WHR (quartiles) and on WHO classification of waist hip ratio at baseline* 
 Waist to Hip Ratio at baseline 
 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Per quartile 
Increase 
Non-obese¥ Obese¥ Per unit increase 
Crohn’s disease         
Pooled age and sex adjusted HR (95% CI) 1.00 1.20 (0.89 – 1.63) 1.30 (0.95 – 1.77) 1.38 (1.00 – 1.90) 1.10 (1.00 – 1.22) 1.00 1.19 (0.93 – 1.53)  1.27 (0.68 – 2.40) 
Pooled MV-adjusted HR (95% CI)∆ 1.00 1.13 (0.84 – 1.51) 1.22 (0.90 – 1.66) 1.28 (0.93 – 1.77) 1.08 (0.98 – 1.19) 1.00 1.14 (0.89 – 1.47) 1.33 (0.56 – 3.16) 
Pooled MV-adjusted HR (95% CI)§ 1.00 1.12 (0.84 – 1.50) 1.19 (0.88 – 1.62) 1.23 (0.88 – 1.71) 1.08 (0.97 – 1.19) 1.00 1.09 (0.85 – 1.40) 1.02 (0.97 – 1.07) 
         
Ulcerative colitis         
Pooled age and sex adjusted HR (95% CI) 1.00 1.09 (0.90 – 1.33) 0.93 (0.74 – 1.14) 1.04 (0.82 – 1.32) 0.99 (0.92 – 1.07) 1.00 1.09 (0.92 – 1.30) 1.21 (0.85 – 1.74) 
Pooled MV-adjusted HR (95% CI)∆ 1.00 1.12 (0.91 – 1.36) 0.93 (0.75 – 1.15) 0.98 (0.77 – 1.24) 0.97 (0.91 – 1.05) 1.00 1.05 (0.89 – 1.25) 1.21 (0.83 – 1.76) 
Pooled MV-adjusted HR (95% CI) § 1.00 1.10 (0.87 – 1.30) 0.91 (0.73 – 1.12) 0.98 (0.77 – 1.25) 0.97 (0.90 – 1.04) 1.00 1.04 (0.87 – 1.25) 1.01 (0.97 – 1.06) 
*Abbreviations: Confidence interval (CI), hazard ratio (HR), World Health Organization (WHO).  I2 values for highest category of WHR and as continuous variable for pooled analyses = 0%. 
¥ Non-obese WHR = female ≤ 0.85, male ≤ 0.90; Obese WHR = female > 0.85, male > 0.90 
∆ Models adjusted for age at baseline (continuous), sex, smoking status (Never/Former/Current), Physical activity (Quartiles), Energy intake (continuous), dietary fiber (continuous) for CD only, dietary fat (continuous) for 
UC only. 
§Models adjusted for age at baseline (continuous), BMI (3 categories 18.5-<25, 25-<30, 30-), sex, smoking status (Never/Former/Current), Physical activity (Quartiles), Energy intake (continuous), dietary fiber (continuous) 























WHAT YOU NEED TO KNOW 
Background and context 
Plausible biological mechanisms imply a role for obesity in the pathogenesis of inflammatory bowel 
disease, but the relationship between obesity and risk of Crohn’s disease (CD) and ulcerative colitis 
(UC) is unclear. 
 
Findings 
In a pooled analysis of 5 prospective cohorts, obesity as defined by body mass index is associated 
with a significant risk of incident of CD but not UC.  
 
Implication for patient care 
The growing burden of obesity may be an important contributor to the increasing incidence of CD 
worldwide with the effects of obesity potentially playing a stronger role in the etiopathogenesis of 
CD compared with UC.  
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